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Plasmodium falciparum parasites that are resistant to artemisinins have been detected in Southeast Asia. Resis-
tance is associated with several polymorphisms in the parasite’s K13-propeller gene. The molecular epidemiol-
ogy of these artemisinin resistance genotypes in African parasite populations is unknown. We developed an
assay to quantify rare polymorphisms in parasite populations that uses a pooled deep-sequencing approach
to score allele frequencies, validated it by evaluating mixtures of laboratory parasite strains, and then used it
to screen P. falciparum parasites from >1100 African infections collected since 2002 from 14 sites across
sub-Saharan Africa. We found no mutations in African parasite populations that are associated with artemisi-
nin resistance in Southeast Asian parasites. However, we observed 15 coding mutations, including 12 novel
mutations, and limited allele sharing between parasite populations, consistent with a large reservoir of naturally
occurring K13-propeller variation. Although polymorphisms associated with artemisinin resistance in P. falcip-
arum in Southeast Asia are not prevalent in sub-Saharan Africa, numerous K13-propeller coding polymor-
phisms circulate in Africa. Although their distributions do not support a widespread selective sweep for an
artemisinin-resistant phenotype, the impact of these mutations on artemisinin susceptibility is unknown and
will require further characterization. Rapid, scalable molecular surveillance offers a useful adjunct in tracking
and containing artemisinin resistance.
Keywords. falciparum malaria; artemisinin resistance; drug resistance; molecular epidemiology.
Received 28 May 2014; accepted 21 July 2014; electronically published 1 Sep-
tember 2014.
Correspondence: Jonathan J. Juliano, MD, Division of Infectious Diseases, CB
7030, Chapel Hill, NC 27599 (jjuliano@med.unc.edu).
The Journal of Infectious Diseases® 2015;211:680–8
© The Author 2014. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. All rights reserved. For Permissions, please e-mail:
journals.permissions@oup.com.
DOI: 10.1093/infdis/jiu467
680 • JID 2015:211 (1 March) • Taylor et al
Global control of falciparum malaria relies upon the high effi-
cacy of artemisinin combination therapies (ACTs) [1]. ACTs
are recommended in nearly all malaria-endemic countries [2].
However, in Southeast Asia, ACT efficacy is threatened by re-
duced Plasmodium falciparum susceptibility to artemisinins,
which clinically manifests as delayed parasite clearance [3].
While thus far restricted to Southeast Asia, this delayed-clearance
phenotype is increasingly common [4] and correlates with in-
creases in ACT failures [5]. Delayed clearance is therefore widely
considered to be associated with clinically significant P. falcipa-
rum artemisinin resistance. The spread of these artemisinin-
resistant parasites could undermine artemisinin-based therapies
and imperil global malaria control.
The artemisinin-resistant phenotype reported in Southeast
Asia has recently been ascribed to mutations in the kelch pro-
peller domains of the parasite gene PF3D7_1343700 (hereafter,
the “K13-propeller gene”) [6]. K13-propeller polymorphisms
are associated with in vitro parasite survival in the presence of
dihydroartemisinin and with delayed clearance in vivo after
artemisinin therapy. In Cambodia, where this delayed parasite
clearance was first reported, 3 polymorphisms—C580Y, R539T,
and Y493H—are prevalent and associated with prolonged par-
asite half-life after treatment. An additional polymorphism,
M476I, was selected in a Tanzanian parasite by cyclic in vitro
artemisinin pressure. Recent allelic exchange experiments, in
which C580Y was introduced into an artemisinin-susceptible
parasite, resulted in in vitro artemisinin resistance [7]. These
data support the use of K13-propeller mutant genotypes as a
marker for reduced parasite susceptibility to artemisinins [8].
Rapid surveillance of parasite populations for drug resistance
can help to inform the selection of drugs by control programs.
Across sub-Saharan Africa, ACT for uncomplicated malaria has
had high cure rates [9, 10], and parasite clearance is rapid in in
vivo studies [11, 12].As an adjunct to in vivo drug efficacy studies,
we recently described a protocol suitable for large-scale molecular
surveillance of drug resistance markers that uses deep sequencing
pools of parasite isolates by second generation sequencing to
quantify P. falciparum alleles [13]. Herein, we report the adapta-
tion and rapid application of this protocol to screen for P. falcip-
arum K13-propeller mutations in >1100 infections from across
sub-Saharan Africa. To our knowledge, this is the first survey of
K13-propeller polymorphisms in African parasites.
METHODS
Design of Pooled Sequencing Protocol
We first sequenced a fragment of the P. falciparum K13-propel-
ler gene in 22 parasites from Anlong Veng, Cambodia [5], and
from the laboratory P. falciparum strain 3D7 (ATCC, Manassas,
VA). We used a hemi-nested protocol to amplify a 751-bp re-
gion (nucleotides 1279–2030, representing codons 427–676)
of PF3D7_1343700, which included described single-nucleotide
polymorphisms recently associated with delayed parasite clear-
ance [6]. In the 25-µL first-round reaction, we used 2.5 µL of the
Roche FastStart Hi-Fidelity Buffer, 0.5 µL of the Roche FastStart
Hi-Fidelity Enzyme, 400 nM of the primers ArtinnerF (GCC
TTGTTGAAAGAAGCAGAA) and ArtouterR (CGCCATTTT
CTCCTCCTGTA), 10 nM of dNTPs, and 5 µL of template.
Cycling conditions were 95°C for 15 minutes, followed by 35
cycles at 94°C for 1 minute, 58°C for 1 minute, and 72°C for
2 minutes, with an extension at 72°C for 5 minutes. The second
round consisted of the primers ArtinnerF and ArtinnerR (GTG
GCAGCTCCAAAATTCAT) and 3 µL of the first-round prod-
uct as template, with otherwise identical constituents and cy-
cling conditions. Products were sequenced using ABI BigDye
Terminator chemistry, aligned to reference PF3D7_1343700
(http://www.plasmodb.org; accessed 12 January 2014), and
scored for polymorphisms by using Sequencher (Gene Codes,
Ann Arbor, MI). After identification of an isolate (Cam91)
containing only the C580Y mutation, we confirmed its mono-
clonality by genotyping at 8 neutral microsatellite loci [14] and
deep sequencing of a polymorphic segment of the P. falciparum
circumsporozoite protein [15].
Control Mixture Amplification and Sequencing
We investigated both the sensitivity and precision of minor
allele frequency (MAF) estimation by amplifying the K13-
propeller gene from mixtures of 3D7 (wild type) and Cam91
(mutant) genomic DNA (gDNA). We first quantified parasite
DNA in each specimen, using a real-time polymerase chain re-
action (PCR) assay [16], and then prepared 6 dilutions of 3D7:
Cam91 gDNA in ratios of 7:1, 15:1, 31:1, 63:1, 127:1, and 255:1;
in these dilutions, the C580Ymutation would be expected to be
present in proportions of 12.5%, 6.25%, 3.13%, 1.56%, 0.78%,
and 0.39%, respectively. From these dilutions, we amplified
the target in duplicate reactions and prepared these products
for sequencing by acoustic shearing to produce 300-bp frag-
ments. Library preparation was done using the Ion Plus Frag-
ment Library Kit and Ion Xpress Barcode Adaptors (Life
Technologies). The final sequencing library consisted of equi-
molar amounts of the 12 bar-coded libraries and was sequenced
on an Ion Torrent 316 chip, using the 400-bp sequencing kit.
Determination of False-Discovery Rate and Setting Minor Allele
Frequency Cutoffs
Because both PCR and Ion Torrent sequencing are error prone,
mitigating the risk of false discovery is critical. Therefore, we
optimized the specificity of minor allele detection by enforcing
a suite of nonsequential quality controls on the reads and their
constituent bases. First, reads were mapped against the refer-
ence sequence by using bowtie2 with default unpaired read set-
tings [17]. Custom python scripts created using pysam were
used to generate a pileup (base-wise multiple alignment), filter
each base for inclusion, and calculate the final frequency of any
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detected minor alleles (Figure 1A) [18]. During filtering, we
minimized common known artifacts from sequencing or mis-
alignment. Therefore, bases were censored if they were within
(1) poorly mapped reads (q < 10); (2) reads of <200 bp; (3)
10 bp of the end of a read, where false mismatches are common;
or (4) reads with poor alignment scores to the reference se-
quence (≤80). Additionally, any minor alleles had to occur on
both forward and reverse strands.
We examined multiple-base Phred score quality cutoffs,
using sequences that were generated from mixtures of parasite
isolates 3D7 and Cam91 (Figure 1B). On the basis of this anal-
ysis, we selected a high cutoff of 34 for the minimum base qual-
ity. Using these criteria, we maintained sufficient base depth to
ensure accuracy of the frequency estimates and high specificity
by setting MAF cutoffs of 0.5% (for known alleles, based on
MalariaGen [19] and work by Ariey et al [6]) or 1.0% (for
novel alleles). These minimum frequency cutoffs are similar
to those reported for variant discovery in human immuno-
deficiency virus genomes [20, 21] and, on the basis of our 12
controls, predict an expected false-discovery rate of <0.6 and
0.1 false calls for known and novel alleles, respectively, across
all 14 experimental pools.
Amplification and Sequencing of Field Parasites
We made 14 pools of P. falciparum gDNA from 14 different
study sites in sub-Saharan Africa collected between 2002 and
2011; each pool comprised between 35 and 273 P. falciparum
infections (Supplementary Table 1). To prepare a pool, we com-
bined 3 µL of gDNA from each parasite isolate after extraction
from a dried blood spot, using either Chelex-100 or a commercial
kit. The K13-propeller fragments were processed as described
above and sequenced on an Ion Torrent 318 chip. For Sanger se-
quencing of selected isolates, we used the PCR, sequencing, and
read scoring protocols described above.
Analysis of Mutations
We scanned sequencing reads for the co-occurrence of muta-
tions in a single read because mutant K13-propeller haplotypes
in Cambodia uniformly harbored a single coding mutation [6].
We used the pysam module to interrogate our quality-filtered
sequencing reads by collating all reads that contributed to
minor allele calls at each base position and then identified the
pairwise intersect of reads involved for all minor allele calls. To
infer the relationships between populations, we used allele fre-
quency estimates at each polymorphic site (n = 23) in each pop-
ulation (n = 14) to calculate pairwise Nei’s chord distances (DA)
[22], using PowerMarker (v3.25) [23]. The DA-derived distance
matrix was used to construct 100 bootstrap replicates from
which a consensus tree was computed using MEGA (v6.0)
[24] and rendered using APE for R [25]. The analysis was
repeated regionally between West Africa (for samples from
Gambia, Ghana, Burkina Faso, and 2 populations in Mali), Cen-
tral Africa (for samples from 4 populations in the Democratic
Republic of the Congo), and East Africa (for samples from
Uganda, Tanzania, Malawi, and 2 populations in Kenya).
Ethics
Original studies were approved by their respective governing
ethics boards (Supplementary Table 1). Molecular testing of
parasites was approved by the University of North Carolina.
RESULTS
Determination of False Allele Discovery Rate
In the analysis of known control mixtures of the 2 clonal lines,
the initial 2 020 741 reads were filtered for quality and artifacts
Figure 1. Sequencing results of a mixture of parasite strains 3D7 and
Cam91. A, Schematic approach and output of quality-filtering program
applied to sequencing reads. B, Kernel density plot of the number of
false-positive nucleotides that would be detected across the length of
our amplicon, using 3 different minimum Phred base quality cutoffs
(q33, q34, and q35) at various minimum percentage minor allele frequency
cutoffs. C, Venn diagram of the number of bases censored by the 5 main
quality metrics (using the q34 filter) applied to the sequencing reads in
panel A.
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to maximize specificity while maintaining sensitivity and accu-
racy (Figure 1A and “Methods” section). Individual base quality
had the greatest impact on coverage and specificity of minor al-
lele detection (Figure 1C). Therefore, we assessed 3 levels of
base quality filtering in conjunction with all other filtering.
To quantify the false-positive rates for each base quality level,
we determined the number of falsely detected alleles exceeding
a given MAF cutoff across all 12 control reactions and deter-
mined the per base rate by dividing this number by the total
number of nucleotides sequenced. This per base rate was mul-
tiplied by the length of the amplicon to determine the number
of false alleles likely detected in a single experimental pool (Fig-
ure 1B). Specificity increased with increasing quality threshold,
but there was minimal gain in specificity with q35, and base
depth declined significantly, impacting allele frequency estimation
and sensitivity and leading us to select q34 as our experimental fil-
ter threshold. Based on q34 error rates, the MAF cutoffs of 0.5%
for known alleles and 1.0% for unknown alleles were chosen for
maximum specificity so that <1 false positive would be expected
across all 14 experimental pools. Also, in the controls, all observed
false positives between the 0.5% and 1% cutoffs were at or near the
0.5% cutoff, suggesting an absence of high-frequency PCRerrors.
In the end, 1 996 507 aligned reads containing 82 787 771 bases
successfully passed our quality filters, resulting in >1000-fold
coverage at >99% of bases among our controls.
Quantification of Allele Frequencies in Laboratory Mixtures
From the control mixtures, the observed frequencies of the
C580Y allele were closely correlated with expected frequencies,
with correlation coefficients of >0.99 and a regression line with
a R2 value of 0.98 (Figure 2). In the template mixture with an ex-
pected frequency of C580Y of 0.39%, the observed frequencies
were 0.33% and 0.24%, indicating that the sequencing and read
analysis quantified MAF accurately and did so at low allele
frequencies.
P. falciparum K13-propeller Mutations in Field Parasites
We next applied the described sequencing approach to parasite
isolates collected in 14 studies across sub-Saharan Africa (Sup-
plementary Table 1). After applying the quality filters described
above, we analyzed 115 463 298 bases and again achieved
>1000-fold coverage at >99% of bases in the amplified region
(Supplementary Figure 1); for these analyses, we used our em-
pirically derived cutoffs (see “Methods and Discussion” sections)
to censor MAFs below 0.5% at previously described polymorphic
loci and below 1% in previously unknown polymorphic loci.
We observed 23 polymorphisms in 21 codons in the 14 para-
site populations: 14 were nonsynonymous mutations, 8 were
synonymous mutations, and 1 encoded a premature stop codon
(Table 1). Six mutations have been described previously: 5 are in
the MalariaGen database, and 1 was reported by Ariey et al [6].
By K13-propeller blade, blades 3 (n = 6) and 5 (n = 4) contained
the greatest number of coding substitutions (Table 1). Parasite
populations harbored 1–5 polymorphisms; this number did not
correlate with the number of parasite isolates in a pool (corre-
lation coefficient = 0.30).
Notably, the C580Y, R539T, or Y493H substitutions that
were associated with delayed parasite clearance in Southeast
Asia were not observed, nor was the M476I mutation that was
selected in vitro in a Tanzanian parasite [6]. The single poly-
morphism we observed that was reported by Ariey et al [6]
was P553L, present in low frequencies in our pools from Kisu-
mu, Kenya, and Machinga, Malawi. In San, Mali, we also ob-
served 2 alternate substitutions at residues that were mutated
in Cambodian parasites: G449D (A in Cambodia [6]) and
R561C (H in Cambodia [6]).
Population Genetics of K13-propeller Mutations
Eighteen of the 23 mutations that we observed were private al-
leles restricted to single parasite populations. These 18 alleles
included the 3 mutations that achieved the highest site frequen-
cies: A557S at 36.3% in Bas-Congo, Democratic Republic of the
Congo; R471R at 9.8% in Kinshasa, Democratic Republic of the
Congo; and V581V at 7.1% in Bas-Congo. Only 5 alleles were
shared between sites: the V520A substitution was most preva-
lent at 13 sites at frequencies of 1.3%–3.3%, and other shared
alleles were present at a maximum of 3 sites.
We confirmed the presence of the A557S allele in Bas-Congo,
using bidirectional Sanger sequencing. The A557S mutation
was present in 1 of 13 isolates selected randomly from the orig-
inal pool of 50.
Figure 2. Expected and observed frequencies of the C580Y substitution
in mixtures of parasite strains 3D7 (C580) and Cam91 (580Y). Gray dia-
monds are proportions of alleles in 2 independent replicates for each mix-
ture; the solid line is a linear regression line fitted to these points, with the
shaded area indicating the error estimate for the line (R2 = 0.98). The hor-
izontal lines indicate the minimum percentage minor allele cutoffs that
were ultimately used for known (dotted) and novel (dashed) loci.
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G449D 1346 G A . . . . . . 5.32 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
C469Ca 1407 C T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.24 . . . . . . 0.87
W470X 1410 G A . . . . . . 5.03 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
R471R 1413 T C . . . . . . . . . . . . . . . . . . . . . 9.79 . . . . . . . . . . . . . . . . . .
Blade 2
G496Ga 1488 T C . . . 5.77 0.78 . . . . . . . . . . . . 1.64 . . . . . . . . . . . . . . . . . .
R513R 1539 T C . . . . . . . . . . . . . . . . . . . . . 1.15 . . . . . . . . . . . . . . . . . .
V520A 1559 T C 2.14 1.65 1.31 1.74 2.05 2.11 1.83 2.19 3.32 . . . 2.18 1.93 2.07 2.03
S522Ca 1564 A T . . . . . . . . . . . . . . . . . . . . . . . . . . . 2.57 . . . . . . . . . . . .
Blade 3
C542Y 1625 G A . . . . . . . . . . . . 1.01 . . . . . . . . . . . . . . . . . . . . . . . . . . .
G544R 1630 G A . . . . . . . . . 1.31 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
G545E 1634 G A . . . 3.17 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
P553La 1658 C T . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.53 . . . . . . 0.59
P553P 1659 G A . . . 4.78 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
A557S 1669 G T . . . . . . . . . . . . . . . 36.31 . . . . . . . . . . . . . . . . . . . . . . . .
R561C 1681 C T . . . . . . 1.14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Blade 4
A578Sb 1732 G T . . . . . . . . . . . . . . . . . . . . . . . . . . . 1.03 . . . . . . . . . . . .
V581V 1743 T C . . . . . . . . . . . . . . . 7.09 . . . . . . . . . . . . . . . . . . . . . . . .
V589V 1767 C T . . . . . . . . . . . . . . . . . . . . . . . . 1.21 . . . . . . . . . . . . . . .
Blade 5
A617T 1849 G A . . . . . . . . . . . . . . . 1.75 . . . . . . . . . . . . . . . . . . . . . . . .
A617V 1850 C T . . . 1.31 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
V637A 1910 T C . . . . . . . . . . . . . . . 3.22 . . . . . . . . . . . . . . . . . . . . . . . .
G638R 1912 G A 1.72 . . . . . . . . . 2.21 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Q654Qa 1962 A G . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.52
Data are the proportion of reads within each population that harbored the indicated mutation. Minor alleles were censored below 1% for novel loci and below 0.5% for known polymorphic loci. Empty cells indicate mutations
that were not observed.
Abbreviation: DRC, Democratic Republic of the Congo.
a Polymorphisms previously reported in the MalariaGen beta release of the Plasmodium falciparum Community Project [19].













In Cambodian parasites, K13-propeller genes did not contain
>1 coding mutation [6]. Nine of our parasite populations har-
bored >1 coding substitution (Table 1). We interrogated the
quality-filtered sequencing reads from these sites, and, similar
to results from Cambodia, coding substitutions did not co-
occur in reads spanning 2 polymorphic loci in 8 of the parasite
populations; only in Bas-Congo did a small fraction of reads
that spanned residues 557 and 617 harbor coding substitutions
at both loci. However, we cannot exclude the possibility of chi-
meric sequencing reads, owing to the limited number of reads
that spanned this 180-bp segment (n = 101) and the frequencies
of the potential parental haplotypes. Therefore, our data largely
support the notion that mutant K13-propeller haplotypes har-
bor only single coding mutations in the sequenced segment.
The geographic prevalences of coding mutations, silent mu-
tations, and wild-type allele proportions suggested that poly-
morphisms were less frequent in East than in Central or West
Africa (Figure 3). We explored the genetic relationships between
K13-propeller alleles within the parasite populations, using a
population genetic allele-based clustering algorithm. In this
analysis, there was no significant differentiation of mutant
alleles between parasite populations. Between 3 populations—
Fukayosi, Tanzania, Siaya, Kenya, and Kinshasa (2006)—the
pairwise DA values were 0 (indicating no genetic differentia-
tion), and the greatest distance (between Bas-Congo and
Kita, Mali) was only 0.0146. Furthermore, a neighbor-joining
tree computed with these distances demonstrated no geographic
clustering of alleles between populations, suggesting no
Figure 3. Epidemiology of Plasmodium falciparum K13-propeller mutations in 14 sub-Saharan African sites. Proportions within each geographic site of
wild-type alleles, coding mutations, and silent mutations. Proportions calculated with the assumption that each K13-propeller haplotype contained only a
single mutation, as observed here and in Cambodia [6]. Abbreviation: DRC, Democratic Republic of the Congo.
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significant spread of K13 polymorphisms (Supplementary
Figure 2). Similar low genetic distances were seen when ana-
lyzed on a regional scale.
DISCUSSION
Our survey of K13-propeller polymorphisms in P. falciparum
captured a diversity of mutations across and within sub-Saharan
African parasite populations. Notably, we did not detect any
polymorphisms that are clearly associated with either artemisi-
nin resistance in Cambodian parasites or with artemisinin tol-
erance in vitro, and we observed only 1 polymorphism that was
shared with those previously reported from Cambodia. Overall,
most polymorphisms encoded nonsynonymous substitutions
but were present at low frequencies and restricted to single geo-
graphic sites; this allelic heterogeneity does not suggest direc-
tional selection resulting from drug pressure. In the short
term, the absence of known molecular markers of artemisinin
resistance augurs favorably for the antimalarial efficacy of
ACTs in Africa. However, it is difficult to predict how soon re-
sistance mutations may appear in Africa, and molecular surveil-
lance can provide a framework to rapidly monitor for the
emergence or importation of resistance alleles.
Ariey et al [6] reported that (1) prolonged parasite survival ex
vivo was associated with the Y493H, I543T, R539T, and C580Y
mutations; (2) in vivo delayed parasite clearance was associated
with the Y493H, R539T, and C580Ymutations; and (3) artemi-
sinin tolerance in vitro was associated with the M476Imutation,
which also indicated that K13-propeller mutations can produce
an artemisinin-resistance phenotype in vitro with an African
parasite genetic background. A subsequent report supports
the causal role of K13-propeller mutations in conferring resis-
tance, because the introduction to a susceptible parasite of the
C580Y substitution prolonged the survival of the parasite in
vitro in the presence of artemisinin [7]. We observed none of
these 5 mutations in our survey of >1000 African parasite sam-
ples. Furthermore, we observed only 1 K13-propeller mutation
(P553L) that was previously reported from Cambodia, and this
mutation was rare both in Cambodia and in Africa. The paucity
of shared mutant alleles between African and Cambodian par-
asites suggests that there exists a large reservoir of K13-propeller
polymorphisms globally.
Despite the allelic diversity of the K13-propeller gene, our
data do not suggest widespread selection for an artemisinin re-
sistance polymorphisms in Africa at the time these samples
were collected. Such a process would be expected to increase fre-
quencies of mutations that confer resistance and, concomitantly,
to reduce allelic heterogeneity through linkage disequilibrium.
For other antimalarials, the loss of allelic diversity at the locus
mediating resistance has accompanied the geographic spread of
P. falciparum resistance to chloroquine [26], pyrimethamine
[27], and sulfadoxine [28]. In contrast, in our data, mutations
did not appear to cluster geographically, likely owing to the pau-
city of allele sharing between parasite populations. Only 5 of 23
polymorphisms were shared between any 2 sites, and although 1
polymorphism (V520A) was detected in 13 of 14 populations,
the other 4 were present in a maximum of 3 sites. Additionally,
in the parasite populations harboring the highest frequencies of
individual coding mutations (from Bas-Congo province and
San), we observed at least 4 other polymorphisms, suggesting
that the high frequency of coding mutations was not coincident
with a loss of other polymorphisms. These observations appear
analogous to data from Cambodia, where it appears that minor
alleles were abundant but regionally circumscribed prior to re-
cent replacement by artemisinin resistance mutations. Because
these mutant alleles have unknown phenotype consequences,
we cannot exclude the possibility that the observed allele fre-
quencies represent incipient sweeps, and further studies are
needed to better characterize this variation.
The function of the K13-propeller of P. falciparum is largely
unknown, and direct predictions of function are precluded by
the diverse functions of kelch-containing proteins in other spe-
cies. Within the K13-propeller gene, mutations clustered in do-
mains similar to those reported from Cambodia, including those
associated with resistance in domains 2, 3, and 4 (Table 1). Two
coding substitutions are particularly notable. First, the A557S
substitution achieved a high frequency (36.3%) in Bas-Congo
province but was absent in other contemporary parasite popula-
tions, including those from neighboring sites in Kinshasa and
Bandundu province. This mutation was confirmed using Sanger
sequencing of individual isolates. The phenotype of this mutation
is unknown, but given its high frequency and position in a K13-
propeller domain that harbored 2 artemisinin resistance substi-
tutions (R539T and I543T) in Cambodia parasites, we suggest
it merits further characterization. Second, in San, we observed
a nonsense mutation at codon 470 in 5% of reads. Presumably,
a K13-propeller protein truncated in the first propeller domain
would manifest a substantial loss of function in the parasite;
such mutations have been observed in the kelch-containing
human gene KEAP1 and have been associated with lung carcino-
ma [29], suggesting biological plausibility. This unusual poly-
morphism also merits further characterization.
The World Health Organization’s Global Plan for Artemisi-
nin Resistance Containment prioritizes the monitoring of ACT
efficacy to detect resistance [30], and this is most credibly quan-
tified using clinical efficacy data. This approach may be limited
by resource constraints [31]. Resource-intensive studies might
be prefaced by molecular surveillance to detect foci of parasites
bearing resistance genotypes that would facilitate targeting of in
vivo and ex vivo investigations. Such molecular surveillance
would ideally include efficient and scalable methods to quantify
parasite alleles.
Our protocol using pooled second-generation sequencing
is sensitive, inexpensive, and scalable. In just over 2 months,
686 • JID 2015:211 (1 March) • Taylor et al
we designed the protocol, piloted it by evaluating laboratory par-
asites, and applied it to field parasites to generate K13-propeller
allele frequencies from >1100 parasites. Traditional genotyping
approaches may not be suitable to detect K13-propeller polymor-
phisms [8]. The polymorphisms associated with an artemisinin-
resistant phenotype are numerous, unlinked, and occur on a
background of allelic diversity. These facts may technically un-
dermine traditional approaches that only interrogate specific al-
leles. Because several independent polymorphisms can produce
the artemisinin-resistant phenotype, ongoing surveillance will
need to detect the appearance of newmutations, shifts in frequen-
cies of existing African variants, and the importation of known
Asian resistance mutations. Although our pooled approach does
not allow direct investigations of individual clinical or molecular
phenotypes, it can easily be followed by K13-propeller gene rese-
quencing to enable more-comprehensive surveillance of the
emergence or importation of resistance genotypes.
Our study had several limitations. Although studies of de-
fined parasite mixtures accurately quantified allele frequencies,
frequency estimates in the field isolates may have been biased by
the varied densities of the input parasites. Nevertheless, in a
prior study using a similar protocol, allele frequencies were
closely correlated with those obtained by Sanger sequencing
of individual isolates [13]. Because both PCR enzymes and sec-
ond-generation sequencing introduce nucleotide errors, many
reads contained errors that could have falsely identified minor
alleles. To mitigate this risk, we (1) used high-fidelity polymer-
ase, (2) empirically designed a quality-assurance algorithm by
using our validation sequencing reactions of clonal parasite
lines to minimize false discovery of alleles, and (3) used this al-
gorithm for reads obtained from field parasites.
In this first large-scale survey of P. falciparummolecular mark-
ers of artemisinin resistance, we found no previously identified
artemisinin resistance mutations in contemporary African para-
site populations. Although the overall frequency of wild-type
K13-propeller genes was high, we identified numerous novel cod-
ing substitutions that are of unclear phenotype. A better under-
standing of the biological and clinical impact of these genotypes
will require coordinated clinical and molecular genetic investiga-
tions. Complementing these studies with ongoing, large-scale
molecular epidemiologic surveillance will enhance our ability to
monitor artemisinin resistance. Together, these integrated efforts
may help forestall the spread of resistance and enhance the global
durability of artemisinin therapies.
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